À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Question clinique
For patients presenting with ischemic stroke, does thrombolysis initiated between 4.5 hours and 9 hours after symptom onset still provide benefit?
L’Essentiel
For patients with ischemic stroke and evidence of salvageable brain tissue by perfusion imaging studies, intravenous alteplase delivered between 4.5 hours and 9 hours after stroke onset, or at time of awakening with stroke symptoms, resulted in a higher percentage of patients with excellent functional status at 90 days as compared with placebo. Not surprisingly, alteplase also caused more symptomatic intracranial bleeds. 1b-
Référence
Plan de l'etude: Randomized controlled trial (double-blinded)
Financement: Government
Cadre: Inpatient (any location)
Sommaire
Current guidelines state that intravenous thrombolysis must be initiated within 4.5 hours after onset of ischemic stroke. In this study, investigators enrolled patients with acute ischemic stroke who presented either between 4.5 and 9 hours after stroke onset or upon awakening with stroke symptoms with time of onset of symptoms unknown. Eligible patients were those with excellent functional status prior to stroke who had evidence of hypo-perfused but salvageable areas of brain tissue detected by perfusion imaging. Using concealed allocation, the investigators randomized patients to receive either intravenous alteplase (n = 113) or matching placebo (n = 112). The trial was terminated early (before the target 310 patients were enrolled) because of loss of equipoise after positive results were found in a similar trial. In the current trial, 65% of patients in both groups awoke with stroke symptoms with time of onset unknown, 25% were treated after 6 hours of known symptom onset, and 10% were treated between 4.5 and 6 hours of symptom onset. After adjustment for baseline factors, the patients who received alteplase were more likely to achieve an excellent functional outcome at 90 days, as indicated by a modified Rankin scale score of 0 or 1 (35.4% in alteplase group vs 29.5% in placebo group; P = .04; number needed to treat = 17). The alteplase group was also more likely to have symptomatic intracranial bleeds (6.2% vs 0.9%; P = .05, number needed to treat to harm = 19). No significant mortality difference was detected.
Reviewer
Nita Shrikant Kulkarni, MD
Assistant Professor in Hospital Medicine
Northwestern University
Chicago, IL